The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

The situation began to escalate after Trump’s trade policy announcement on 5 April.

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the ...